Loading
A phase 1 trial of Mavorixafor and Ibrutinib in Waldenström macroglobulinaemia, run by X4 Pharmaceuticals, completed.
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 is a phase 1 interventional study registered as NCT04274738 by X4 Pharmaceuticals, with 16 participants recorded, started 2020-04-30 and reaching its primary completion in 2022-10-31. Interventions recorded: Mavorixafor, Ibrutinib. Conditions recorded: Waldenstrom's Macroglobulinemia.
Linked to the drug Mavorixafor because the registry names it among its interventions and Waldenström macroglobulinaemia among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares X4 Pharmaceuticals, Mavorixafor and the tag pipeline.
Shares Waldenström macroglobulinaemia and the tag pipeline.
Shares Ibrutinib and the tag pipeline.
Shares Ibrutinib and the tag pipeline.
Shares Ibrutinib and the tag pipeline.
Shares Waldenström macroglobulinaemia and the tag pipeline.
Shares Ibrutinib and the tag pipeline.
Shares Ibrutinib and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/